A combination of osimertinib and trastuzumab-emtansine, a conjugate of the monoclonal antibody trastuzumab (Herceptin) and the cytotoxic agent DM1, was reported to overcome osimertinib resistance in T790M-positive EGFR-mutated NSCLC cell lines that gained HER2 amplification.101 Similarly, combining osimertinib with drugs targeting other downstream pathways, such as a BRAF inhibitor64 or the AXL inhibitor cabozantinib,102 constitutes a promising strategy for overcoming osimertinib resistance, but clinical evidence regarding the effectiveness of these approaches is lacking so far. Here, ERBB2 is linked to non-small cell lung carcinoma.